{
  "doc_id": "PIIS0923753425000730",
  "chunks": [
    {
      "text": "Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A.Vogel1,2,3, S. L. Chan4, L. A. Dawson5,6, R. K. Kelley7, J. M. Llovet8,9,10,T. Meyer11,12, J. Ricke13, L. Rimassa14,15, G. Sapisochin16,V.Vilgrain17,18,",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "0_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "J. Zucman-Rossi19 & M. Ducreux20,21, on behalf of the ESMO Guidelines Committee(cid:1) 1DepartmentofGastroenterology,HepatologyandEndocrinology,HannoverMedicalSchool,Hannover,Germany;2DivisionofHepatology,TorontoGeneralHospital, Toronto;3DivisionofMedicalOncology,PrincessMargaretCancerCentre,Toronto,Canada;4StateKeyLaboratoryofTranslationalOncology,DepartmentofClinical Oncology,SirYKPaoCentreforCancer,PrinceofWalesHospital,TheChineseUniversityofHongKong,HongKong,China;5RadiationMedicineProgram,Princess MargaretCancerCentre,UniversityHealthNetwork,Toronto;6DepartmentofRadiationOncology,UniversityofToronto,Toronto,Canada;7HelenDillerFamily ComprehensiveCancerCenter,UniversityofCalifornia,SanFrancisco;8MountSinaiLiverCancerProgram,DivisionofLiverDiseases,IcahnSchoolofMedicineat MountSinai,NewYork,USA;9LiverCancerTranslationalResearchGroup,LiverUnit,Institutd’InvestigacionsBiomèdiquesAugustPiiSunyer(IDIBAPS),HospitalClínic, UniversitatdeBarcelona,Barcelona;10InstitucióCatalanadeRecercaiEstudisAvançats(ICREA),Barcelona,Spain;11DepartmentofOncology,RoyalFreeHospital, London;12UCLCancerInstitute,UniversityCollegeLondon,London,UK;13KlinikundPoliklinikfürRadiologie,Ludwig-Maximilians-UniversitätMünchen,Munich, Germany;14DepartmentofBiomedicalSciences,HumanitasUniversity,PieveEmanuele,Milan;15MedicalOncologyandHematologyUnit,HumanitasCancerCenter, IRCCSHumanitasResearchHospital,Rozzano,Milan,Italy;16DepartmentofSurgery,UniversityofToronto,Toronto,Canada;17CentredeRecherchesurl’Inflammation U1149,UniversitéParisCité,Paris;18DepartmentofRadiology,BeaujonHospital,APHPNord,Clichy;19CentredeRecherchedesCordeliers,UniversitéParisCité, SorbonneUniversité,INSERM,Paris;20INSERMU1279,UniversitéParis-Saclay,Villejuif;21DepartmentofCancerMedicine,GustaveRoussy,Villejuif,France Availableonline20February2025 Key words: diagnosis, guideline, hepatocellular carcinoma",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "0_0_1",
        "oversized_split": true
      }
    },
    {
      "text": "(HCC), imaging, treatment INCIDENCE AND EPIDEMIOLOGY (cid:3) Antiviral therapy is recommended in all patients with active HBV who are diagnosed with HCC [II, A]. Livercanceristhesixthmostcommoncancerandthethird leading cause of cancer deaths globally.1,2 Hepatocellular (cid:3) Direct-actingantiviraltherapyisgenerallyrecommended for patients with active HCV who are diagnosed with cancer (HCC) accounts for 80% of the global liver cancer burden,with>900000newcasesandanage-standardised HCC, but the timing should be individualised [IV, B].",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "0_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "rate of 7.3 per 100000 in 2020.2 Over the past two decades,therehasbeenareductionintheincidenceofHCCin\nAsiancountriesincludingJapan,ChinaandKorea,3butinci- SURVEILLANCE denceisrisinginEuropeandNorthAmerica.4,5HCCshowsa\nSurveillance of HCC involves the repeated application of strong male preponderance and incidence increases proscreening tools in patients at risk for HCC and aims to\ngressivelywithadvancingage.2Informationontheaetiology\nreduce mortality. The success of surveillance is influenced\nof HCC is available in Supplementary Material Section 1, bytheincidenceofHCCinthetargetpopulation,availability\navailableat\nand acceptance of efficient diagnostic tests and availability of effective treatment.",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": 1
      }
    },
    {
      "text": "Surveillance for HCC can be\nconsideredwhentheannualriskofHCCis>1%peryearin\nRecommendations\npatientswithcirrhosisand>0.2%peryearinthosewithout\n(cid:3) DuetotheassociationofHCCwithchronicliverdisease,\ncirrhosis.6 In Asian patients, serum HBV DNA >10 000\nuniversal vaccination at birth against hepatitis B virus copies/ml has been associated with a higher annual riskof\n(HBV) [II, A] and early antiviral treatment for HBV and\nHCC compared with patients with a lower viral load.7 The\nhepatitis C virus (HCV) [III, A] are recommended. PAGE-B score estimates the risk of HCC in patients with chronic HBVreceiving entecavir or tenofovir, based on age,\n*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via sex and platelet count.8 Patients with HCV and advanced\nGinevra4,CH-6900Lugano,Switzerland\nE-mail:clinicalguidelines@esmo.org(ESMOGuidelinesCommittee).",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": 2
      }
    },
    {
      "text": "fibrosis remain at increased risk for HCC even after\nachieving sustained virological response following antiviral\n5Note:ApprovedbytheESMOGuidelinesCommittee:October2018,last\nupdate February 2025.This publication supersedes thepreviously published treatment and should, therefore, remain in a surveillance\nversiondAnnOncol.2018;29(suppl4):IV238-IV255. programme.9\n0923-7534/©2025EuropeanSociety forMedicalOncology. Published by\nLiver ultrasound (US) is a standard tool for HCC surveil-\nElsevierLtd.Allrightsarereserved,includingthosefortextanddatamining,AI\ntraining,andsimilartechnologies. lance but has limited sensitivity and specificity, particularly\nVolume36 - Issue 5 - 2025 491\nin livers with significant steatosis.10 In Western countries MR contrast agents is mediated by organic anionic transand less experienced centres, the sensitivity of US for porting polypeptides expressed on the sinusoidal mem-\nidentifying early-stage HCC is considerably lower than in brane of functional hepatocytes and loss of hepatocellular moreexperiencedcentres.11Addingmeasurementofserum function occurs early during hepatocarcinogenesis, before\na -fetoprotein (AFP) to US can provide an improvement in tumour neoangiogenesis.16 If imaging criteria are not met\nthe early HCC detection rate, but at the price of false- on the first imaging examination (e.g. CT), repeat imaging\npositive results.12 Cell-free DNA-based liquid biopsies have can be considered after 3 months for lesions (cid:4)1 cm.",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": 3
      }
    },
    {
      "text": "For\nshown encouraging preliminary results for the early detec- largerlesions,imagingshouldberepeatedusingadifferent tion of HCC but remain to be prospectively validated.13 A modality (e.g. MRI) or a biopsy should be carried out. randomised controlled trial (RCT) compared surveillance Further details on diagnostic imaging for HCC are available\n(USandserumAFPmeasurementsevery6months)withno inSupplementaryMaterialSection2andTableS2,available surveillance in Chinese patients with chronic HBV infec- at\ntion.14 Despite low compliance with the surveillance programme (55%), HCC-related mortality was reduced by 37% Pathology\nin the surveillance arm. Regarding the most appropriate\nThe increasing number of HCCs related to metabolic surveillance interval, a randomised studycomparing 3- and\ndysfunction-associatedsteatoticliverdiseaseintheabsence\n6-month schedules did not report any differences in of cirrhosis can make diagnosis challenging, as it can be\ndetection of early HCC.15\ndifficult to discriminate between HCC and other liver tumours, particularly less common primary malignant liver\nRecommendations\ntumours such as cholangiocarcinoma, combined hep-\n(cid:3) SurveillanceforHCCisrecommendedinallpatientswith atocholangiocarcinoma and fibrolamellar HCC.17 Furthercirrhosis,irrespectiveofitsaetiology,ifliverfunctionand more, differential diagnosis between HCC and benign\ncomorbidities allow tumour treatment [II, A].",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": 4
      }
    },
    {
      "text": "nodules may be difficult and pathological examination is (cid:3) HCC surveillance is recommended for patients with required to rule out high- or low-grade cirrhotic dysplastic chronic HBV infection and a moderate or high HCC risk nodules and hepatocellular adenoma, particularly for lescore (e.g. PAGE-B) at the onset of nucleoside analogue sions that are difficult to resect.18 A precise differential therapy [II, A]. diagnosis is, therefore, important since non-HCC patients (cid:3) HCCsurveillanceshouldincludeabdominalUS(ormulti- require specific management and therapeutic strategies. phase cross-sectional imaging if available) every InthecaseofspecificriskfactorsforHCC,abiopsyofthe 6 months, with or without AFP evaluation [II, A]. non-tumour liver tissue and/or specialised molecular and",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "5_0_0",
        "oversized_split": true
      }
    },
    {
      "text": "(cid:3) Liquid biopsy and analysis of circulating tumour DNA genetic tests can optimise surveillance of the patient and (ctDNA) cannot be recommended for HCC surveillance their relatives. Patients with undiagnosed genetic disease [IV, D]. and a mild phenotype (particularly those with a familial context of liver disease or tumour) could benefit from genetic counselling and tests for metabolic diseases (e.g. DIAGNOSIS, PATHOLOGY AND MOLECULAR BIOLOGY haemochromatosis, alpha-1 antitrypsin deficiency, Diagnosis porphyria, maturity-onset diabetes of the young). Paired tumour and non-tumour liver biopsy should be carried out Diagnosis methods vary according to clinical context and in an expert centre by an",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "5_0_1",
        "oversized_split": true
      }
    },
    {
      "text": "experienced radiologist or hepwhether the patient is at risk for HCC (Supplementary atologistusingan18-gaugeneedle tominimise side-effects Table S1, available at such as bleeding and tumour seeding, which are rare.19 2025.02.006). High-risk patients include those with Panels of immunohistochemistry markers can help assess cirrhosis and chronic HBV infection. In such settings, nondiagnosis, prognosis and specific subtypes of tumours. invasive imaging-based criteria on computed tomography (CT), magnetic resonance imaging (MRI) or contrast- Molecular biology enhanced US (CEUS) can provide a diagnosis without formal pathological proof; therefore, technique optimisa- HCC is a heterogeneous disease that includes various tion is critical. pathological and molecular subtypes.",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "5_1_0",
        "oversized_split": true
      }
    },
    {
      "text": "Molecular classifica- For diagnosis of HCC, multiphasic CT and MRI follow the tions have shown that the varied natural history at the technical recommendations of the CT and MRI Liver Imag- origin of each subtype can be identified by mutations in ing Reporting and Data System (LI-RADS)® v2018. Any cancerdrivergenes,includingTERT,TP53,CTNNB1,ARID1A, magnetic resonance (MR) contrast agent may be used. RB1, FGF19 and CCND1.20 These oncogenic defects are Multiphasic MRI offers several advantages over CT, translated in molecular classification, enabling categoincludingdepictionofmoreancillaryfeaturesfavouringthe risationofHCCinmorehomogeneoussubgroupsaccording diagnosisofHCCorothermalignancies,suchasfatinmass, to their specific proliferative rate, level of differentiation moderate T2 hyperintensity and restricted diffusion. It also and signalling pathway activation.",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": "5_1_1",
        "oversized_split": true
      }
    },
    {
      "text": "Recent proof-of-concept\nallows hepatocyte function measurement using hep- studies have shown that molecular-guided therapy using atobiliary contrast agents; internalisation of hepatobiliary next-generationsequencing(NGS)isfeasible;somepatients Manufacture from materials of any heading, except that of the product",
      "metadata": {
        "doc_id": "PIIS0923753425000730",
        "heading": "SPECIAL ARTICLE",
        "start_page": 1,
        "end_page": 2,
        "created_date": "20",
        "country": "EU",
        "source_type": "clinical_guideline",
        "original_file_path": "hcc/clinical guidelines/EU/PIIS0923753425000730_cleaned.json",
        "split_index": 6,
        "merged": true
      }
    }
  ]
}